复方鳖甲软肝片联合当飞利肝宁片治疗肝纤维化116例疗效评价

Efficacy Evaluation of Compound Biejia Ruangan Tablet and Dangfei Liganning Tablet on Hepatic Fibrosis

目的评价复方鳖甲软肝片联合当飞利肝宁片治疗肝纤维化的临床疗效。方法选择慢性肝炎肝纤维化代偿期患者232例,随机分为治疗组和对照组,各116例。两组患者均予以常规护肝治疗,治疗组加用复方鳖甲软肝片和当飞利肝宁片,对照组加用护肝片,疗程均为6个月。记录治疗后症状、体征、肝功能及血清透明质酸(HA)、Ⅲ型前胶原肽(PCⅢ)、甘氨胆酸(CG)、Ⅳ型胶原(ⅣC)、影像学改变等情况。结果与治疗前比较,治疗组HA,PCⅢ,CG,ⅣC水平均显著下降,与对照组比较,差异也有统计学意义(P<0.05)。结论复方鳖甲软肝片联合当飞利肝宁片能减轻患者症状、改善肝功能和肝纤维化,是治疗肝纤维化的有效药物。

Objective To evaluate the clinical effect of Fufang Biejia Ruangan Tablet ( FB ) and Dangfei Liganning Tablet ( DF ) in treating hepatic fibrosis. Methods 232 patients with chronic hepatitis hepatic fibrosis compensated stage were selected and randomly di-vided into the treatment group and the control group,116 cases in each group. The two groups all received the routine hepatic protec-tive therapy. And the treatment group was added with FB and DF, while the control group was added with Hugan Tablet. The course of treatment lasted for 6 months. The clinical symptoms, physical signs, liver function, hyaluronic acid ( HA ) , procollagen Ⅲ( PCⅢ) , cholyg-lycine ( CG ) , collagen type Ⅳ(ⅣC ) and ultrasound image change after therapy were recorded in both two groups. Results Levels of serum HA, PCⅢ, CG,ⅣC in the treatment group were decreased significantly, which showed the statistically significant differences com-pared with the control group ( P﹤0. 05 ) . Conclusion The combination treatment of FB and DF can alleviate the patient's symptoms, improves the hepatic function and liver fibrosis, and is one of effective drugs for treating liver fibrosis.